SLC transporter expression for predicting chemotherapeutic effectiveness in gastric cancer

2015 Fiscal Year Final Research Report

• Project/Area Number: 25460455
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Human pathology
• Research Institution: Kobe University
• Principal Investigator: KAMOSHIDA SHINGO 神戸大学, 保健学研究科, 教授 (70351020)
• Co-Investigator(Kenkyū-buntansha): SHINTANI Michiko (TANAKA Michiko) 神戸大学, 大学院保健学研究科, 助教 (40207147)
• Co-Investigator(Renkei-kenkyūsha): YOSHIKAWA Takaki 地方独立行政法人神奈川県立病院機構神奈川県立がんセンター, 消化器外科, 医長 (30336573)
• Research Collaborator: NAKA Ayano ; TAKEDA Risa ; OGANE Naoki ; KAMEDA Yoichi ; AOYAMA Toru ; SHIMAKATA Takaaki ; KAWAMURA Jumpei ; DENDA Tamami ; KAWAI Kenji ; KUWAO Sadahito ; YANAGITA Emmy ; ITOH Tomoo ; SAKAMAKI Kuniko ; HAYASHI Yurie
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: 胃癌 / 化学療法 / 効果予測 / SLCトランスポーター / 免疫組織化学

Outline of Final Research Achievements

First, we evaluated OCT2 expression in advanced gastric cancers (GCs) treated with neoadjuvant chemotherapy (NAC) with S-1/cisplatin. Expression levels of OCT2 were immunohistochemically assessed and correlated with pathologic response. The rate of high expression levels of OCT2 (OCT2High) was significantly higher in responders compared with non-responders. In addition, OCT2High was the sole independent predictor of response. These results suggest that OCT2High may represent a potential predictor of response to NAC with S-1/cisplatin in GC.
Next, we evaluated expression levels of a panel of SLC transporters in α-fetoprotein (AFP)-producing GCs and conventional GCs. The rates of high expression levels of ENT1 (ENT1High) and OAT2 (OAT2High) were statistically higher in AFP-producing GCs compared with conventional GCs. These results suggest that patients with AFP-producing GC could potentially benefit from gemcitabine/fluoropyrimidine combination chemotherapy.

Free Research Field

腫瘍病理学、免疫組織化学、臨床細胞学